Advertisement
U.S. markets open in 5 hours 30 minutes

Eledon Pharmaceuticals, Inc. (ELDN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.8800+0.0400 (+2.17%)
At close: 04:00PM EST
1.8800 0.00 (0.00%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Hanging Man

Hanging Man

Previous Close1.8400
Open1.8800
Bid0.0000 x 1000
Ask0.0000 x 900
Day's Range1.8000 - 1.8800
52 Week Range1.0700 - 2.9500
Volume25,668
Avg. Volume70,924
Market Cap45.492M
Beta (5Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)-5.4400
Earnings DateMar 28, 2024 - Apr 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ELDN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Eledon Pharmaceuticals, Inc.
    Daily – Vickers Top Insider Picks for 05/13/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the Company’s Compensation Committee granted 42,500 restricted stock units (RSUs) and stock options to purchase an aggregate of 90,000 common shares, at a per share exercise price of $1.77, the closing price of Eledon’s common stock on the grant date, to one employee. The RSUs and stock options were granted as inducements material to the new employee entering employment w

  • GlobeNewswire

    Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

    Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated Dosed first participants in Phase 2 BESTOW trial in kidney transplantation Tegoprubart dosed in second-ever pig to human xenotransplant procedure IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced a summary of 2023 accomplish

  • Simply Wall St.

    Will Eledon Pharmaceuticals (NASDAQ:ELDN) Spend Its Cash Wisely?

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...